



FOR IMMEDIATE RELEASE

Media Contact

Ian Stone

Russo Partners

Tel: +1 619 528 2220

ian.stone@russopartnersllc.com

Phase 1 Data on Alder Biopharmaceuticals' ALD518 to be Presented at 5th Cachexia Conference

*Data presented by Professor Stephen Clarke to demonstrate
pharmacokinetic and early efficacy data of IL-6 inhibiting antibody*

BOTHELL, Wash., December 7, 2009 – Alder Biopharmaceuticals, Inc., announced today that Professor Stephen Clarke, Ph.D. will present data from a Phase 1 study of the company's IL-6 inhibiting monoclonal antibody at the 5th Cachexia Conference in Barcelona, Spain.

The oral presentation, titled, "A phase I, pharmacokinetic (PK) and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer", is scheduled for 11 a.m. CET on Monday, December 7. The abstract will also be presented as a poster at the conference.

"This data demonstrates early signs of the potential for the treatment of cancer associated cachexia and fatigue through inhibition of IL-6 with ALD518," said Randy Schatzman, president and CEO of Alder. "We look forward to continuing to pursue this and related indications on our own while expanding our pipeline in new areas with our core antibody technologies."

About Alder

Alder Biopharmaceuticals, Inc. uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling

partners through the out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Schering-Plough, Seattle Genetics, Genmab, and two additional non-disclosed large pharmaceutical companies. For more information, visit www.alderbio.com.